Patients & Caregivers

Patient with a kind-looking carer smiling at each other

We are the provider of the THERAKOS^TM CELLEX^TM Photopheresis System: an integrated system used for the delivery of extracorporeal photopheresis (ECP).

Our THERAKOS™ CELLEX™ Photopheresis System delivers extracorporeal photopheresis (also known as ECP*), a treatment for patients with a range of immune-mediated diseases

We have been developing this treatment and advancing the technology of our THERAKOS™ CELLEX™ Photopheresis System for over 30 years

We are committed to optimising the delivery of ECP* for patients and the healthcare professionals that administer it

*ECP stands for extracorporeal photopheresis (‘extracorporeal’ means outside the body).

Download Our Patient Brochure

Your video guide to ECP

Watch our ECP video series and get the information you are looking for

FIND OUT MORE

Pensive looking healthcare professional with a patient

What is extracorporeal photopheresis (ECP)?

Extracorporeal Photopheresis, also known as ECP, is a treatment that works with the immune system.

DISCOVER MORE

Three cells in the front of the picture with a cluster of cells further back

How does extracorporeal photopheresis (ECP) work?

Discover how extracorporeal photopheresis (ECP) harnesses the power of the immune system. The exact mechanism of action is not known and continues to be investigated to be better understood.

DISCOVER MORE

Positive clinician engaging with male patient

What do I need to know before starting treatment?

If you have been prescribed a course of extracorporeal photopheresis (ECP), find out what you need to know before beginning treatment

DISCOVER MORE

Patient stories

Hear from patients who have undergone extracorporeal photopheresis treatments with the THERAKOS^TM CELLEX^TM Photopheresis System

DISCOVER MORE

Older female patient smiling with an older male healthcare professional

FAQ

See our frequently-asked questions

DISCOVER MORE

THERAKOS^TM Photopheresis Systems are CE marked for the administration of photopheresis.
The information provided in this website should not be used as a substitute for medical advice from a healthcare professional.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Patients & Caregivers

We are the provider of the THERAKOSTM CELLEXTM Photopheresis System: an integrated system used for the delivery of extracorporeal photopheresis (ECP).

Your video guide to ECP

What is extracorporeal photopheresis (ECP)?

How does extracorporeal photopheresis (ECP) work?

What do I need to know before starting treatment?

Patient stories

FAQ

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

We are the provider of the THERAKOS^TM CELLEX^TM Photopheresis System: an integrated system used for the delivery of extracorporeal photopheresis (ECP).

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS